KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Non-Current Liabilities (2018 - 2025)

Historic Other Non-Current Liabilities for Acadia Pharmaceuticals (ACAD) over the last 11 years, with Q3 2025 value amounting to $13.9 million.

  • Acadia Pharmaceuticals' Other Non-Current Liabilities fell 935.26% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year decrease of 935.26%. This contributed to the annual value of $18.1 million for FY2024, which is 1920.51% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Other Non-Current Liabilities of $13.9 million as of Q3 2025, which was down 935.26% from $28.5 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $28.5 million in Q2 2025 and a low of $3.6 million during Q1 2021
  • Its 5-year average for Other Non-Current Liabilities is $10.9 million, with a median of $9.3 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Acadia Pharmaceuticals' Other Non-Current Liabilities was 13093.35% (2025), while the steepest drop was 935.26% (2025).
  • Acadia Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $7.0 million in 2021, then rose by 29.0% to $9.1 million in 2022, then soared by 66.93% to $15.1 million in 2023, then increased by 19.21% to $18.1 million in 2024, then dropped by 23.08% to $13.9 million in 2025.
  • Its last three reported values are $13.9 million in Q3 2025, $28.5 million for Q2 2025, and $20.0 million during Q1 2025.